Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORE-RCC: Zanzalintinib + Nivolumab in Locally Advanced/Inoperable Clear Cell Renal Cell Carcinoma
NCT06794229Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in clear cell renal cell carcinoma (ccRCC). Started Oct 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06794229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794229.